Avandamet Film-Coated Tablets

On 23 September 2010, the European Medicines Agency recommended the suspension of the marketing authorisations for rosiglitazone-containing anti-diabetes medicines.

Advice for healthcare professionals and patients:

• Prescribers should put in place a system to ensure that all patients are reviewed and changed to another suitable treatment in line with NICE recommendations.
• While this change could happen at the next routine appointment, prescribers may wish to see patients sooner rather than later in order to reduce patient anxiety.
• Patients who are concerned should not stop their treatment but should contact the healthcare professional supervising their diabetic treatment.

Further information can be found on the MHRA website:

http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/
CON094121